"Cagevy has been enthusiastically received by patients, physicians, and policymakers, and the launch is gathering momentum across all regions," said Stuart Arbuckle, Vertex's chief operating officer.
In sickle cell disease, patients don't produce healthy hemoglobin due to errors in the gene, resulting in crescent-shaped red blood cells that block blood flow.
As a result of sickle cell disease, people experience extreme pain crises that can last for hours or days, often requiring hospitalization.
Casgevy debuted with a price tag of $2.2 million in the US, reflecting the high cost associated with pioneering gene-editing therapies.
Collection
[
|
...
]